Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Salarius Pharmaceuticals, Inc. (SLRX : NSDQ)

• Company Description    Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals Inc., formerly known as Flex Pharma Inc., is based in Houston, Texas. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $0.65 Daily Weekly Monthly 20 Day Moving Average: 263,321 shares Shares Outstanding: 5.86 (millions) Market Capitalization: $3.80 (millions) Beta: 0.33 52 Week High: $55.05 52 Week Low: $0.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.47% -25.34% 12 Week -85.12% -85.36% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2450 Holcombe Blvd. Suite X - Houston,TX 77021 USA ph: 713-913-5608 fax: - jcain@allianceadvisors.com http://www.salariuspharma.com

• General Corporate Information    Officers David J. Arthur - President and Chief Executive Officer William K. McVicar - Chairman Tess Burleson - Director Arnold C. Hanish - Director Paul Lammers - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 79400X503 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/20/26 Share - Related Items Shares Outstanding: 5.86 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.33 Market Capitalization: $3.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/20/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.14 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 84.11% vs. Previous Quarter: 73.17% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -401.05 06/30/25 - -556.47 ROA 12/31/25 - - 09/30/25 - -155.77 06/30/25 - -192.35 Current Ratio 12/31/25 - - 09/30/25 - 3.28 06/30/25 - 0.61 Quick Ratio 12/31/25 - - 09/30/25 - 3.28 06/30/25 - 0.61 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 4.50 06/30/25 - -5.85 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - -

Powered by Zacks Investment Research ©